If a company isn't IPO-ready, it better be M&A-ready.
Nanna Lüneborg of Forbion
Forbion General Partner Nanna Lüneborg and Forbion co-founder Sander Slootweg sit down with Bloomberg Intelligence analyst Sam Fazeli to explain Forbion’s blueprint for success in Europe’s maturing biotech ecosystem. From incubating CNS-focused gene therapy startups to executing €100M+ financing rounds, Forbion’s thesis is rooted in scientific rigor and commercially sound exits. They also share how Europe’s capital scarcity offers hidden advantages, and why late-stage buyers still pay up for must-have innovation.